Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) FCF Margin (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed FCF Margin for 6 consecutive years, with 13484.7% as the latest value for Q3 2025.

  • Quarterly FCF Margin changed N/A to 13484.7% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 3947.64% through Dec 2025, down 496298.0% year-over-year, with the annual reading at 3666.65% for FY2025, 584577.0% down from the prior year.
  • FCF Margin for Q3 2025 was 13484.7% at Outlook Therapeutics, up from 790.61% in the prior quarter.
  • The five-year high for FCF Margin was 13484.7% in Q3 2025, with the low at 790.61% in Q2 2025.